Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since May 14 · below the Ichimoku cloud · RSI 34 · MACD above its signal · at its 52-week low
| 3.06 | 52-week high | +332.63% |
| 1.26 | Previous month high | +78.14% |
| 0.8660 | R3 (classic) | +22.44% |
| 0.8330 | R2 (classic) | +17.77% |
| 0.8140 | Previous week high | +15.09% |
| 0.8000 | Previous day high | +13.11% |
| 0.7700 | R1 (classic) | +8.86% |
| 0.7520 | Previous month low | +6.32% |
| 0.7370 | Pivot | +4.20% |
| 0.7073 | Price now | |
| 0.7040 | Previous day low | −0.47% |
| 0.7040 | Previous week low | −0.47% |
| 0.7040 | 52-week low | −0.47% |
| 0.6740 | S1 (classic) | −4.71% |
| 0.6410 | S2 (classic) | −9.37% |
| 0.5780 | S3 (classic) | −18.28% |
None of the 29 investors followed here reported a position in MIST in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MIST trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 15, 2026 | Oliveto Joseph GerardChief Executive Officer | Sale at price 2.26 per share. | 36.5K | $82.49K |
| Jan 25, 2026 | Oliveto Joseph GerardChief Executive Officer | Sale at price 1.93 - 2.32 per share. | 167.6K | $375.31K |
| Jan 25, 2026 | Muller Lorenz AndrewOfficer | Sale at price 1.93 - 2.32 per share. | 64.7K | $145.85K |
| Jan 25, 2026 | Hasija AmitChief Financial Officer | Sale at price 1.93 - 2.32 per share. | 70.3K | $158.21K |
| Jan 25, 2026 | Bharucha DavidOfficer | Sale at price 1.93 - 2.32 per share. | 70.3K | $158.21K |
| Jan 25, 2026 | Nelson Jeffrey EdwardChief Operating Officer | Sale at price 1.93 - 2.32 per share. | 70.3K | $158.21K |
| Jan 25, 2026 | Oliveto Joseph GerardChief Executive Officer | — | 66.6K | — |
| Jan 25, 2026 | Muller Lorenz AndrewOfficer | — | 20.1K | — |
| Jan 25, 2026 | Hasija AmitChief Financial Officer | — | 20.1K | — |
| Jan 25, 2026 | Bharucha DavidOfficer | — | 20.1K | — |
| Jan 25, 2026 | Nelson Jeffrey EdwardChief Operating Officer | — | 20.1K | — |
| Jan 7, 2026 | Oliveto Joseph GerardChief Executive Officer | Sale at price 2.25 per share. | 43.5K | $97.88K |
| Dec 11, 2025 | Oliveto Joseph GerardChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 280K | — |
| Dec 11, 2025 | Muller Lorenz AndrewOfficer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Dec 11, 2025 | Hasija AmitChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Dec 11, 2025 | Bharucha DavidOfficer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Dec 11, 2025 | Nelson Jeffrey EdwardChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Dec 8, 2025 | Muller Lorenz AndrewOfficer | Stock Gift at price 0.00 per share. | 25K | — |
| Jul 10, 2025 | Papa Joseph CDirector | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Jul 10, 2025 | Oliveto Joseph GerardChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 66.7K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.4 | -10.5 | -30.4 | 51.3 | -21.1 | -5.6 | -17.2 | 4.5 | -25.3 | -18.3 | −65.0% | ||
| 2025 | -16.5 | -17.3 | -50.9 | 65.0 | 22.7 | 19.8 | -25.3 | 26.9 | 8.7 | -4.0 | 40.1 | -24.9 | −14.4% |
| 2024 | -4.2 | 5.0 | 6.5 | -7.8 | -9.1 | -12.0 | 9.1 | -1.4 | 7.0 | -4.6 | 37.2 | 18.6 | +41.3% |
| 2023 | -7.6 | -13.7 | 24.7 | -7.9 | 8.5 | -27.7 | 13.3 | -17.0 | 15.7 | -17.4 | 30.5 | -50.0 | −57.8% |
| 2022 | 6.0 | -28.7 | 29.7 | 3.6 | -15.6 | 9.6 | 21.1 | 16.2 | 6.1 | -45.4 | -2.2 | -19.3 | −39.5% |
| 2021 | 10.1 | -2.6 | -19.5 | 1.2 | 3.2 | -9.1 | 3.6 | 6.5 | -5.9 | -1.4 | -2.8 | 19.7 | −2.2% |
| 2020 | 37.7 | -13.8 | -90.3 | 63.6 | 5.0 | 19.6 | 130.2 | -11.0 | -5.4 | -21.3 | 16.3 | 0.0 | −58.2% |
| 2019 | 31.2 | -40.3 | 39.5 | -17.5 | 2.6 | -11.9 | -5.1 | −22.7% |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Buy / hold / sell counts